Immunization Safety Office, Division of Healthcare Quality Promotion, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention (CDC), United States.
Immunization Safety Office, Division of Healthcare Quality Promotion, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention (CDC), United States.
Vaccine. 2020 Jan 29;38(5):1137-1143. doi: 10.1016/j.vaccine.2019.11.023. Epub 2019 Nov 26.
Vaccines administered into or too close to underlying joint structures have the potential to cause shoulder injuries. Limited data exist on the epidemiology of such events.
To describe case reports of atypical shoulder pain and dysfunction following injection of inactivated influenza vaccine (IIV).
We searched the Vaccine Adverse Event Reporting System (VAERS) database from July 2010 to June 2017 for reports of atypical shoulder pain and dysfunction following IIV. When identifying reports, we made no assumptions about true incident injury or causality with respect to vaccination. Pain had to begin <48 h after vaccination and signs and symptoms had to continue for >7 days to differentiate from self-limited local reactions. We conducted descriptive analysis.
We identified 1220 reports that met our case definition (2.0% of all IIV reports, range 1.5%-2.5% across influenza seasons). Median age was 52 years (range 16-94) and most patients (82.6%) were female. Shoulder pain (44.1%), injected limb mobility decreased (40.8%), joint range of motion decreased (21.2%), rotator cuff syndrome (9.2%), and bursitis (9.0%) were frequently reported. In 86.6% of reports, signs and symptoms had not resolved by the time of report submission. In reports that included descriptions suggesting contributing factors (n = 266), vaccination given "too high" on the arm was cited in 81.2%. Nearly half (n = 605, 49.6%) of reports described a healthcare provider evaluation. Treatments included non-narcotic analgesics, physical therapy, and corticosteroid injection. Vaccinations were most commonly administered in a pharmacy or retail store (41.0%) or doctor's office or hospital (31.6%).
Reports of atypical shoulder pain and dysfunction following IIV were uncommon, considering the amount of IIV use, and stable across influenza seasons. While specific etiology of cases is unknown, improperly administered vaccine, which is preventable, might be a factor. Prevention strategies include education, training, and adherence to best practices for vaccine administration.
接种于或过于接近关节结构下的疫苗可能会导致肩部损伤。关于此类事件的流行病学数据有限。
描述接种灭活流感疫苗(IIV)后出现非典型肩部疼痛和功能障碍的病例报告。
我们从 2010 年 7 月至 2017 年 6 月在疫苗不良事件报告系统(VAERS)数据库中搜索了 IIV 后出现非典型肩部疼痛和功能障碍的报告。在识别报告时,我们对疫苗接种与真实事件损伤或因果关系没有任何假设。疼痛必须在接种后 <48 小时开始,并且症状和体征必须持续 >7 天,才能与自限性局部反应区分开来。我们进行了描述性分析。
我们确定了符合我们病例定义的 1220 份报告(所有 IIV 报告的 2.0%,各流感季节范围为 1.5%-2.5%)。中位年龄为 52 岁(范围 16-94 岁),大多数患者(82.6%)为女性。肩部疼痛(44.1%)、注射肢体活动度降低(40.8%)、关节活动度降低(21.2%)、肩袖综合征(9.2%)和滑囊炎(9.0%)经常报告。在 86.6%的报告中,在报告提交时,症状和体征尚未缓解。在包含提示促成因素描述的报告中(n=266),81.2%的报告提到疫苗接种在手臂上“过高”。近一半(n=605,49.6%)的报告描述了医疗保健提供者的评估。治疗包括非麻醉性镇痛药、物理治疗和皮质类固醇注射。疫苗接种最常在药房或零售店(41.0%)或医生办公室或医院(31.6%)进行。
考虑到 IIV 的使用量,接种 IIV 后出现非典型肩部疼痛和功能障碍的报告并不常见,且在各流感季节较为稳定。虽然具体病因尚不清楚,但可预防的不当接种疫苗可能是一个因素。预防策略包括教育、培训和遵守疫苗接种最佳实践。